Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the Spear Therapeutics fourth quarter and full year 2024 earnings conference call. At this time, all participants are in listen-only mode. Following the company's formal remarks, we will open up the call for questions. Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and for further information related to today's announcement on the Spear Therapeutics website at www.speartherapeutics.com. At this time, I would like to turn the call over to Shai Biren, Senior Director, Investor Relations. Mr. Biren, please go ahead. Thank you, operator, and thank you all for participating in today's conference call. This afternoon, Sparrow Therapeutics released financial results and provided a business update for the fourth quarter and full year 2024. The press release is available on the investor page of the Sparrow Therapeutics website. Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our actual clinical programs, future results, progress, timing, performances, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with our business and factors that could cause or contribute to such differences are described in detail in Sparrow Therapeutics' filings with the SEC, including in the risk factors section of its earnings report on Form 10-K for the year ended December 31, 2024, filed with the SEC today. Joining me on the call today are Esther Ajavelu, our Interim Chief Executive Office...